tiprankstipranks
Trending News
More News >
Anika Therapeutics, Inc. (ANIK)
:ANIK
US Market

Anika Therapeutics (ANIK) Income Statement

Compare
172 Followers

Anika Therapeutics Income Statement

Last quarter (Q3 2025), Anika Therapeutics's total revenue was $27.82M, a decrease of -28.22% from the same quarter last year. In Q3, Anika Therapeutics's net income was $-2.33M. See Anika Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 119.91M$ 120.79M$ 113.83M$ 147.79M$ 130.46M
Gross Profit
$ 76.00M$ 82.53M$ 73.22M$ 82.94M$ 69.03M
Operating Expenses
$ 81.10M$ 81.69M$ 69.55M$ 80.33M$ 97.35M
Depreciation and Amortization
$ 8.12M$ 14.22M$ 14.49M$ 14.32M$ 13.46M
EBITDA
$ 3.02M$ 15.06M$ 18.16M$ -4.16M$ -1.00M
Operating Income
$ -5.10M$ 844.00K$ 3.67M$ 2.62M$ -28.32M
Other Income/Expenses
$ 2.34M$ 2.31M$ 654.00K$ -188.00K$ -302.00K
Pretax Income
$ -2.76M$ 3.16M$ 4.32M$ 2.43M$ -28.62M
Net Income
$ -56.38M$ -82.67M$ -14.86M$ 4.13M$ -23.98M
Per Share Metrics
Basic EPS
$ -3.83$ -5.64$ -1.02$ 0.29$ -1.69
Diluted EPS
$ -3.83$ -5.64$ -1.02$ 0.28$ -1.69
Weighted Average Shares Outstanding
14.72M 14.66M 14.56M 14.40M 14.22M
Weighted Average Shares Outstanding (Diluted)
14.72M 14.66M 14.56M 14.63M 14.22M
Currency in USD

Anika Therapeutics Earnings and Revenue History